We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

PCR-Based Gastroenteritis Diagnostic Assay Receives European Marketing Approval

By LabMedica International staff writers
Posted on 06 Oct 2014
Print article
Image: Mobidiag’s new Amplidiag product line encompasses innovative multiplex diagnostic tests for gastrointestinal infections (Photo courtesy of Mobidiag).
Image: Mobidiag’s new Amplidiag product line encompasses innovative multiplex diagnostic tests for gastrointestinal infections (Photo courtesy of Mobidiag).
A PCR-based test that optimizes screening of gastroenteritis-causing bacteria directly from stool samples has been certified for marketing in Europe as a CE-IVD product according to Directive 98/79/EC regarding in vitro diagnostic medical devices.

The Mobidiag Ltd. (Espoo, Finland) Amplidiag Bacterial GE test utilizes well-established qPCR (quantitative polymerase chain reaction) technology for the rapid qualitative detection of eight gastroenteritis-causing bacteria directly from stool samples without requiring pre-culturing of the samples.

Amplidiag Bacterial GE rapidly detects eight of the most common and important enteric bacterial pathogens with a single assay carried out on DNA extracted from the same stool sample and enables same-day reporting of results. In addition to Campylobacter, Salmonella, Shigella/EIEC, and Yersinia, the test also detects the diarrheagenic E. coli strains: enteropathogenic E. coli (EPEC), enteroaggregative E. coli (EAEC), enterohemorrhagic E. coli (EHEC) and enterotoxigenic E. coli (ETEC).

Amplidiag Bacterial GE was validated by assaying 1,235 patient samples and 125 spiked samples in a two-center performance evaluation study conducted in Sweden and Finland. The results showed an overall sensitivity of 99.0% and specificity of 99.9%, when compared with routine stool culture and independent nucleic acid-based methods. Amplidiag Bacterial GE did not give any false negative findings when results were compared with stool culture.

Related Links:

Mobidiag Ltd.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.